Prevalence of depression and depressive symptoms in patients with systemic lupus erythematosus: Iranian experience.
Psychiatric disorders including depression represent clinical manifestation of systemic lupus erythematosus (SLE). Recognition of depression in SLE patients is of utmost importance since it is treatable and can be of fatal consequences if unrecognized. This study was conducted to determine the prevalence of depression and depressive symptoms in SLE patients in terms of age, gender, disease duration and severity, and duration of steroid treatment in SLE patients. Eighty-five SLE patients (77 women, 8 men) with verified SLE diagnosis completed Beck's depression inventory, a self-reported measure of depression. Clinical data on disease and treatment were obtained from patient files. In total, 60% of patients achieved scores indicating depression. The most common depressive symptoms in participants were fatigue and weakness (88.2%), irritability (82.3%), sadness (77.6%), and somatic preoccupation (76.4%), while the least common symptoms were weight loss (34.1%), low level of energy (28.2%), and suicide ideation (10.5%). There was a significant difference between the disease activity and the severity of depression (P = 0.0001). Our findings show higher prevalence of depression in our sample in comparison with previous studies, suggesting that the prevalence of depression varies across different populations. Severity of depression increases with more severe disease course.
Department of Internal Medicine, Ali-ebne-Abitaleb Hospital, Zahedan University of Medical Sciences, Zahedan, Iran. zah_zakeri@yahoo.com
Zahra
Z
Zakeri
Mansoor
M
Shakiba
Behzad
B
Narouie
Nikol
N
Mladkova
Mohammad
M
Ghasemi-Rad
Alireza
A
Khosravi
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D000367:Age Factors; D016009:Chi-Square Distribution; D003863:Depression / Q000175:diagnosis / Q000453:epidemiology* / Q000523:psychology; D005260:Female; D006801:Humans; D007492:Iran / Q000453:epidemiology; D008180:Lupus Erythematosus, Systemic / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology* / Q000523:psychology; D008297:Male; D011237:Predictive Value of Tests; D015995:Prevalence; D011569:Psychiatric Status Rating Scales; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D017678:Sex Distribution; D012737:Sex Factors; D013256:Steroids / Q000627:therapeutic use; D013997:Time Factors; D055815:Young Adult
D013256:Steroids
Rheumatology (Oxford). 2002 Feb;41(2):184-8
11886968
Arthritis Care Res. 1998 Feb;11(1):23-31
9534490
Autoimmun Rev. 2007 Jun;6(6):421-6
17537389
Psychol Rep. 2002 Jun;90(3 Pt 2):1091-6
12150389
Medicine (Baltimore). 1968 Jul;47(4):337-69
5212395
Neurol India. 2006 Mar;54(1):75-7
16679649
Am J Cardiol. 2002 Dec 15;90(12):1279-83
12480034
Ann Rheum Dis. 2003 Jan;62(1):58-60
12480670
Psychosom Med. 1993 Mar-Apr;55(2):219-28
8475237
Arthritis Rheum. 2006 Aug 15;55(4):628-35
16874786
Rheumatology (Oxford). 2004 Dec;43(12):1580-6
15367746
Ann Rheum Dis. 1975 Oct;35(5):398-406
1234407
Lupus. 1994 Jun;3(3):181-6
7951303
Arthritis Rheum. 2009 Feb 15;61(2):240-6
19177526
QJM. 1999 May;92(5):283-6
10615483
Compr Psychiatry. 2007 Jan-Feb;48(1):14-9
17145276
Arthritis Rheum. 2009 Jun 15;61(6):822-9
19479699
Am Psychol. 1997 Jan;52(1):25-31
9017929
Arthritis Rheum. 1992 Apr;35(4):411-6
1567490
Afr J Med Med Sci. 2009 Mar;38(1):33-8
19722426
Medicine (Baltimore). 1976 Jul;55(4):323-39
781466
Lupus. 1994 Feb;3(1):31-5
8025583
Psychosom Med. 1972 May-Jun;34(3):207-20
5034129
Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):695-700
18077068
Nihon Rinsho. 2001 Aug;59(8):1578-82
11519163
Rheumatology (Oxford). 2009 May;48(5):576-81
19286698
Aust N Z J Med. 1988 Aug;18(5):679-84
3245822
Rheumatology (Oxford). 2001 Jun;40(6):695-8
11426030
Z Rheumatol. 2004 Apr;63(2):122-30
15112090
J Affect Disord. 1983 Nov;5(4):319-32
6319464